Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker

Mariko Kawakami, Koji Kawakami, Jan Kasperbauer, Lucinda L. Hinkley, Mamoru Tsukuda, Scott E. Strome, Raj K. Puri

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Previous studies have demonstrated that approximately 30% of squamous cell carcinoma of the head and neck (SCCHN) cell lines express high levels of interleukin-13 receptor(s) (IL-13R). However, the incidence, expression level, and significance of IL-13R expression in human tumor specimens is not known. In addition, it is not known whether normal head and neck tissues express IL-13R. In this study, we evaluated the expression of IL-13R subunits (IL-13Rα1, IL-13Rα2, and IL-4Rα in 337 surgically excised specimens of SCCHN and normal head and neck tissues. Specimens were obtained from 139 patients with SCCHN and 16 patients with benign tonsil disorders from two centers in the United States and Japan and evaluated with immunohistochemistry and in situ hybridization. Extensive analysis demonstrated that the majority of SCCHN tumors uniformly expressed low levels of IL-13Rα1 chain; however, 77% of the tumors expressed moderate to high levels of IL-4Rα, which forms a signaling complex with IL-13Rα1 chain. On the other hand, 33% of SCCHN tumors expressed moderate to high levels of IL-13Rα2 chain. Using tissue array from 99 patients, we observed that the expression levels of IL-13Rα2 and IL-4Rα were significantly higher in SCCHN than in normal head and neck tissues (P < 0.005). Detailed analysis of clinicopathological features demonstrated a positive statistically significant correlation between IL-13Rα2 expression and clinically advanced primary SCCHN tumor (T4; Tumor-Node-Metastasis classification; P < 0.05). However, there was no correlation among IL-13R expression and sex, age of patients, stage of lymph node metastasis, squamous cell carcinoma grade, or allergic history. Taken together, this study suggests that IL-13R may be involved in SCCHN tumor progression, and 33% of IL-13Rα2-positive SCCHN cases may be targeted by IL-13 cytotoxin and IL-13R-targeted agent.

Original languageEnglish (US)
Pages (from-to)6381-6388
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number17
StatePublished - Dec 15 2003

Fingerprint

Interleukin-13 Receptors
Head and Neck Neoplasms
Neoplasms
Neck
Head
Neoplasm Metastasis
Carcinoma, squamous cell of head and neck
Interleukin-13
Palatine Tonsil
Cytotoxins
In Situ Hybridization
Squamous Cell Carcinoma
Japan
Lymph Nodes
History
Immunohistochemistry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kawakami, M., Kawakami, K., Kasperbauer, J., Hinkley, L. L., Tsukuda, M., Strome, S. E., & Puri, R. K. (2003). Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker. Clinical Cancer Research, 9(17), 6381-6388.

Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker. / Kawakami, Mariko; Kawakami, Koji; Kasperbauer, Jan; Hinkley, Lucinda L.; Tsukuda, Mamoru; Strome, Scott E.; Puri, Raj K.

In: Clinical Cancer Research, Vol. 9, No. 17, 15.12.2003, p. 6381-6388.

Research output: Contribution to journalArticle

Kawakami, M, Kawakami, K, Kasperbauer, J, Hinkley, LL, Tsukuda, M, Strome, SE & Puri, RK 2003, 'Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker', Clinical Cancer Research, vol. 9, no. 17, pp. 6381-6388.
Kawakami M, Kawakami K, Kasperbauer J, Hinkley LL, Tsukuda M, Strome SE et al. Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker. Clinical Cancer Research. 2003 Dec 15;9(17):6381-6388.
Kawakami, Mariko ; Kawakami, Koji ; Kasperbauer, Jan ; Hinkley, Lucinda L. ; Tsukuda, Mamoru ; Strome, Scott E. ; Puri, Raj K. / Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 17. pp. 6381-6388.
@article{3836e8f04f684b21b04a2791e595feaf,
title = "Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker",
abstract = "Previous studies have demonstrated that approximately 30{\%} of squamous cell carcinoma of the head and neck (SCCHN) cell lines express high levels of interleukin-13 receptor(s) (IL-13R). However, the incidence, expression level, and significance of IL-13R expression in human tumor specimens is not known. In addition, it is not known whether normal head and neck tissues express IL-13R. In this study, we evaluated the expression of IL-13R subunits (IL-13Rα1, IL-13Rα2, and IL-4Rα in 337 surgically excised specimens of SCCHN and normal head and neck tissues. Specimens were obtained from 139 patients with SCCHN and 16 patients with benign tonsil disorders from two centers in the United States and Japan and evaluated with immunohistochemistry and in situ hybridization. Extensive analysis demonstrated that the majority of SCCHN tumors uniformly expressed low levels of IL-13Rα1 chain; however, 77{\%} of the tumors expressed moderate to high levels of IL-4Rα, which forms a signaling complex with IL-13Rα1 chain. On the other hand, 33{\%} of SCCHN tumors expressed moderate to high levels of IL-13Rα2 chain. Using tissue array from 99 patients, we observed that the expression levels of IL-13Rα2 and IL-4Rα were significantly higher in SCCHN than in normal head and neck tissues (P < 0.005). Detailed analysis of clinicopathological features demonstrated a positive statistically significant correlation between IL-13Rα2 expression and clinically advanced primary SCCHN tumor (T4; Tumor-Node-Metastasis classification; P < 0.05). However, there was no correlation among IL-13R expression and sex, age of patients, stage of lymph node metastasis, squamous cell carcinoma grade, or allergic history. Taken together, this study suggests that IL-13R may be involved in SCCHN tumor progression, and 33{\%} of IL-13Rα2-positive SCCHN cases may be targeted by IL-13 cytotoxin and IL-13R-targeted agent.",
author = "Mariko Kawakami and Koji Kawakami and Jan Kasperbauer and Hinkley, {Lucinda L.} and Mamoru Tsukuda and Strome, {Scott E.} and Puri, {Raj K.}",
year = "2003",
month = "12",
day = "15",
language = "English (US)",
volume = "9",
pages = "6381--6388",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Interleukin-13 Receptor α2 Chain in Human Head and Neck Cancer Serves as a Unique Diagnostic Marker

AU - Kawakami, Mariko

AU - Kawakami, Koji

AU - Kasperbauer, Jan

AU - Hinkley, Lucinda L.

AU - Tsukuda, Mamoru

AU - Strome, Scott E.

AU - Puri, Raj K.

PY - 2003/12/15

Y1 - 2003/12/15

N2 - Previous studies have demonstrated that approximately 30% of squamous cell carcinoma of the head and neck (SCCHN) cell lines express high levels of interleukin-13 receptor(s) (IL-13R). However, the incidence, expression level, and significance of IL-13R expression in human tumor specimens is not known. In addition, it is not known whether normal head and neck tissues express IL-13R. In this study, we evaluated the expression of IL-13R subunits (IL-13Rα1, IL-13Rα2, and IL-4Rα in 337 surgically excised specimens of SCCHN and normal head and neck tissues. Specimens were obtained from 139 patients with SCCHN and 16 patients with benign tonsil disorders from two centers in the United States and Japan and evaluated with immunohistochemistry and in situ hybridization. Extensive analysis demonstrated that the majority of SCCHN tumors uniformly expressed low levels of IL-13Rα1 chain; however, 77% of the tumors expressed moderate to high levels of IL-4Rα, which forms a signaling complex with IL-13Rα1 chain. On the other hand, 33% of SCCHN tumors expressed moderate to high levels of IL-13Rα2 chain. Using tissue array from 99 patients, we observed that the expression levels of IL-13Rα2 and IL-4Rα were significantly higher in SCCHN than in normal head and neck tissues (P < 0.005). Detailed analysis of clinicopathological features demonstrated a positive statistically significant correlation between IL-13Rα2 expression and clinically advanced primary SCCHN tumor (T4; Tumor-Node-Metastasis classification; P < 0.05). However, there was no correlation among IL-13R expression and sex, age of patients, stage of lymph node metastasis, squamous cell carcinoma grade, or allergic history. Taken together, this study suggests that IL-13R may be involved in SCCHN tumor progression, and 33% of IL-13Rα2-positive SCCHN cases may be targeted by IL-13 cytotoxin and IL-13R-targeted agent.

AB - Previous studies have demonstrated that approximately 30% of squamous cell carcinoma of the head and neck (SCCHN) cell lines express high levels of interleukin-13 receptor(s) (IL-13R). However, the incidence, expression level, and significance of IL-13R expression in human tumor specimens is not known. In addition, it is not known whether normal head and neck tissues express IL-13R. In this study, we evaluated the expression of IL-13R subunits (IL-13Rα1, IL-13Rα2, and IL-4Rα in 337 surgically excised specimens of SCCHN and normal head and neck tissues. Specimens were obtained from 139 patients with SCCHN and 16 patients with benign tonsil disorders from two centers in the United States and Japan and evaluated with immunohistochemistry and in situ hybridization. Extensive analysis demonstrated that the majority of SCCHN tumors uniformly expressed low levels of IL-13Rα1 chain; however, 77% of the tumors expressed moderate to high levels of IL-4Rα, which forms a signaling complex with IL-13Rα1 chain. On the other hand, 33% of SCCHN tumors expressed moderate to high levels of IL-13Rα2 chain. Using tissue array from 99 patients, we observed that the expression levels of IL-13Rα2 and IL-4Rα were significantly higher in SCCHN than in normal head and neck tissues (P < 0.005). Detailed analysis of clinicopathological features demonstrated a positive statistically significant correlation between IL-13Rα2 expression and clinically advanced primary SCCHN tumor (T4; Tumor-Node-Metastasis classification; P < 0.05). However, there was no correlation among IL-13R expression and sex, age of patients, stage of lymph node metastasis, squamous cell carcinoma grade, or allergic history. Taken together, this study suggests that IL-13R may be involved in SCCHN tumor progression, and 33% of IL-13Rα2-positive SCCHN cases may be targeted by IL-13 cytotoxin and IL-13R-targeted agent.

UR - http://www.scopus.com/inward/record.url?scp=0347594130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347594130&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 6381

EP - 6388

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -